title: [Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications].
abstract: Aspirin is recommended as cardiovascular disease prevention in patients with diabetes mellitus. Due to the increased risk of bleeding and because of the hypothesis that there could be a worsening of microvascular complications related to aspirin, there has been observed an important underutilization of the drug. However, it is now known that aspirin is not associated with a deleterious effect on diabetic retinopathy and there is evidence indicating that it also does not affect renal function with usual doses (150 mg/d). On the other hand, higher doses may prove necessary, since recent data suggest that diabetic patients present the so called "aspirin resistance". The mechanisms of this resistance are not yet fully understood, being probably related to an abnormal intrinsic platelet activity. The employment of alternative antiplatelet strategies or the administration of higher aspirin doses (150-300 mg/d) should be better evaluated regarding effective cardiovascular disease prevention in diabetes as well as the possible effects on microvascular complications.
authors.affiliation: Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS.
authors.forename: Eduardo G
authors.initials: EG
authors.lastname: Camargo
authors.forename: Jorge Luiz
authors.initials: JL
authors.lastname: Gross
authors.forename: Letícia S
authors.initials: LS
authors.lastname: Weinert
authors.forename: Joel
authors.initials: J
authors.lastname: Lavinsky
authors.forename: Sandra P
authors.initials: SP
authors.lastname: Silveiro
mesh_terms: D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011322:Primary Prevention
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin